CHICAGO — Teprotumumab, an IGF-1 receptor antagonist antibody, demonstrated improvement of double vision in patients with thyroid eye disease, according to a study presented here.
If approved by the FDA, teprotumumab (Horizon Pharma) would be the first drug with an indication for thyroid eye disease, Raymond S. Douglas, MD, PhD, said at the American Academy of Ophthalmology annual meeting.
In the phase 2 trial, 42 patients were treated with the study drug and 45 patients made up the placebo control arm. At week 24, which marked the end of the (Read more...)
Uncategorized